m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT00180
 [1], [2], [3]
m6A modification ADAR1 ADAR1 METTL3 Methylation : m6A sites Direct Enhancement RNA modification CTNNB1 CTNNB1 ADAR Methylation : modification sites
m6A Modification:
m6A Regulator Methyltransferase-like 3 (METTL3) WRITER
 Regulator Info 
m6A Target Interferon-inducible protein 4 (ADAR1)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type RNA modification (RNAMod)  >> Adenosine-to-Inosine editing (A-to-I)
Epigenetic Regulator Interferon-inducible protein 4 (ADAR1) WRITER View Details
Regulated Target Catenin beta-1 (CTNNB1/Beta-catenin) View Details
Crosstalk Relationship m6A  →  A-to-I Enhancement
Crosstalk Mechanism m6A modification directly impacts RNA modification through modulating the expression level of RNA modification regulator
Crosstalk Summary METTL3 methylates Interferon-inducible protein 4 (ADAR1) mRNA, thereby enhancing its protein expression, which subsequently promotes ADAR mediated A-to-I RNA editing of the Catenin beta-1 (CTNNB1/Beta-catenin) transcript.
Responsed Drug Recombinant human endostatin
 Drug Info 
Pathway Response mRNA surveillance pathway hsa03015
RNA degradation hsa03018
Cell Process RNA stability
In-vitro Model
 MGG8 Glioblastoma Homo sapiens CVCL_D1H4
U-87MG ATCC Glioblastoma Homo sapiens CVCL_0022
U-118MG Astrocytoma Homo sapiens CVCL_0633
K-562 Chronic myelogenous leukemia Homo sapiens CVCL_0004
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
Catenin beta-1 (CTNNB1/Beta-catenin) 4 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name Recombinant human endostatin Approved [4]
Synonyms
Endostar; Endu; Recombinant human endostatin (cancer); YH-16; Recombinant human endostatin (cancer), Shandong Simcere Medgenn
    Click to Show/Hide
MOA Modulator
External Link
TTD: D05YAG
 Compound Name CEQ-508 Phase 1/2 [5]
Synonyms
CEQ-501; TkRNAis (oral, familial adenomatous polyposis/colon cancer), Cequent; TkRNAis (oral, familial adenomatous polyposis/colon cancer), Marina
    Click to Show/Hide
External Link
TTD: D00GBZ
 Compound Name C 82 Phase 1/2 [6]
Synonyms
N-(4-Chlorophenyl)-2H-triazol-4-amine; SCHEMBL15831502; C82
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 75202656
TTD: D0DA5M
 Compound Name Tegavivint Phase 1 [7]
Synonyms
1227637-23-1; 18AP231HUP; 2,7-bis(((3R,5S)-3,5-dimethylpiperidin-1-yl)sulfonyl)anthracene-9,10-dione dioxime; 9,10-Anthracenedione, 2,7-bis(((3R,5S)-3,5-dimethyl-1-piperidinyl)sulfonyl)-, 9,10-dioxime, rel-; AKOS032946684; BC2059; BC-2059; BDBM50108103; BS-14778; CHEMBL3601411; CS-0039507; D71173; HY-109103; N-[3,6-bis[[(3S,5R)-3,5-dimethylpiperidin-1-yl]sulfonyl]-10-nitrosoanthracen-9-yl]hydroxylamine; NSC785527; NSC-785527; rel-2,7-Bis(((3R,5S)-3,5-dimethylpiperidin-1-yl)sulfonyl)anthracene-9,10-dione dioxime; SCHEMBL14947676; Tegatrabetan; Tegavivint; Tegavivint [INN]; TEGAVIVINT [WHO-DD]; UNII-18AP231HUP
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 46212391
TTD: D54WUR
References
Ref 1 N?-Methyladenosine Landscape of Glioma Stem-Like Cells: METTL3 Is Essential for the Expression of Actively Transcribed Genes and Sustenance of the Oncogenic Signaling. Genes (Basel). 2019 Feb 13;10(2):141. doi: 10.3390/genes10020141.
Ref 2 ADAR1 is a new target of METTL3 and plays a pro-oncogenic role in glioblastoma by an editing-independent mechanism. Genome Biol. 2021 Jan 28;22(1):51. doi: 10.1186/s13059-021-02271-9.
Ref 3 ADAR1 may be involved in the proliferation of acute myeloid leukemia cells via regulation of the Wnt pathway. Cancer Manag Res. 2019 Sep 20;11:8547-8555. doi: 10.2147/CMAR.S210504. eCollection 2019.
Ref 4 Endostar, a modified recombinant human endostatin, suppresses angiogenesis through inhibition of Wnt/Beta-catenin signaling pathway. PLoS One. 2014 Sep 18;9(9):e107463. doi: 10.1371/journal.pone.0107463. eCollection 2014.
Ref 5 Current Progress of siRNA/shRNA Therapeutics in Clinical Trials. Biotechnol J. 2011 September; 6(9): 1130-1146.
Ref 6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 7 Tegavivint and the beta-Catenin/ALDH Axis in Chemotherapy-Resistant and Metastatic Osteosarcoma. J Natl Cancer Inst. 2019 Nov 1;111(11):1216-1227.